Get the Stockscreener App
2.18
2.35%
0.05
After Hours:
2.18
Minerva Neurosciences Inc stock is traded at $2.18, with a volume of 10,855.
It is up +2.35% in the last 24 hours and up +23.86% over the past month.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
See More
Previous Close:
$2.13
Open:
$2.11
24h Volume:
10,855
Relative Volume:
0.52
Market Cap:
$15.25M
Revenue:
-
Net Income/Loss:
$-33.65M
P/E Ratio:
-0.4899
EPS:
-4.45
Net Cash Flow:
$-20.83M
1W Performance:
-7.23%
1M Performance:
+23.86%
6M Performance:
+29.76%
1Y Performance:
-20.73%
1-Day Range:
$2.10
$2.1818
1-Week Range:
$2.10
$2.31
52-Week Range:
$1.15
$3.00
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1601 TRAPELO ROAD, WALTHAM, MA
Compare NERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
2.18 | 15.03M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
How to interpret RSI for Minerva Neurosciences Inc. stock2025 Buyback Activity & Daily Profit Maximizing Trade Tips - Newser
Combining price and volume data for Minerva Neurosciences Inc.Trade Risk Assessment & Low Volatility Stock Recommendations - Newser
Risk vs reward if holding onto Minerva Neurosciences Inc.July 2025 Momentum & Community Consensus Picks - Newser
Minerva Neurosciences Inc. stock outlook for YEARTrade Entry Summary & Verified Short-Term Plans - Newser
Analyzing drawdowns of Minerva Neurosciences Inc. with statistical toolsWeekly Trading Summary & Consistent Return Investment Signals - Newser
Should you wait for a breakout in Minerva Neurosciences Inc.Market Performance Report & Free Safe Entry Trade Signal Reports - Newser
Will a bounce in Minerva Neurosciences Inc. offer an exitPortfolio Performance Report & Safe Capital Growth Plans - Newser
What data driven models say about Minerva Neurosciences Inc.’s future2025 Key Lessons & AI Forecasted Entry and Exit Points - Newser
Sector ETF performance correlation with Minerva Neurosciences Inc.Long Setup & Weekly Return Optimization Plans - Newser
Using Python tools to backtest Minerva Neurosciences Inc. strategiesEarnings Growth Summary & Consistent Return Strategy Ideas - Newser
Is this a good reentry point in Minerva Neurosciences Inc.Earnings Trend Report & Daily Technical Stock Forecast Reports - Newser
Can volume confirm reversal in Minerva Neurosciences Inc.2025 Fundamental Recap & Risk Controlled Stock Alerts - Newser
What the charts say about Minerva Neurosciences Inc. today2025 Price Targets & Low Risk Entry Point Tips - Newser
Applying Wyckoff theory to Minerva Neurosciences Inc. stockJuly 2025 Review & Technical Buy Zone Confirmation - Newser
Trend analysis for Minerva Neurosciences Inc. this weekJuly 2025 Spike Watch & Verified Swing Trading Watchlist - Newser
What institutional flow reveals about Minerva Neurosciences Inc.July 2025 Momentum & Accurate Trade Setup Notifications - Newser
Best data tools to analyze Minerva Neurosciences Inc. stockMarket Risk Summary & Free Low Drawdown Momentum Trade Ideas - Newser
How to manage a losing position in Minerva Neurosciences Inc.Risk Management & Safe Entry Zone Identification - Newser
using data models to predict minerva neurosciences inc. stock movementJuly 2025 Spike Watch & High Yield Stock Recommendations - Newser
Does Minerva Neurosciences Inc. show high probability of reboundJuly 2025 Chart Watch & Risk Adjusted Buy and Sell Alerts - Newser
Analyzing Minerva Neurosciences Inc. with multi timeframe chartsGlobal Markets & AI Driven Price Predictions - Newser
Quantitative breakdown of Minerva Neurosciences Inc. recent moveJuly 2025 Big Picture & Real-Time Chart Breakout Alerts - Newser
How to build a custom watchlist for Minerva Neurosciences Inc.July 2025 WrapUp & Free Daily Entry Point Trade Alerts - Newser
Smart tools for monitoring Minerva Neurosciences Inc.’s price actionGold Moves & Daily Profit Focused Stock Screening - Newser
Is Minerva Neurosciences Inc. stock poised for growthSwing Trade & Daily Stock Trend Reports - Newser
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):